QIAGEN Debt to Equity Ratio 2010-2022 | QGEN

Current and historical debt to equity ratio values for QIAGEN (QGEN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. QIAGEN debt/equity for the three months ending March 31, 2022 was 0.46.
QIAGEN Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-03-31 $2.94B $3.24B 0.91
2021-12-31 $3.05B $3.10B 0.99
2021-09-30 $3.03B $3.01B 1.01
2021-06-30 $2.93B $2.98B 0.98
2021-03-31 $2.91B $2.85B 1.02
2020-12-31 $3.07B $2.80B 1.10
2020-09-30 $3.06B $2.71B 1.13
2020-06-30 $2.67B $2.62B 1.02
2020-03-31 $2.69B $2.49B 1.08
2019-12-31 $2.70B $2.54B 1.06
2019-09-30 $2.68B $2.47B 1.08
2019-06-30 $2.75B $2.63B 1.05
2019-03-31 $2.81B $2.61B 1.08
2018-12-31 $3.11B $2.64B 1.18
2018-09-30 $2.77B $2.53B 1.10
2018-06-30 $2.79B $2.52B 1.10
2018-03-31 $2.53B $2.58B 0.98
2017-12-31 $2.50B $2.54B 0.98
2017-09-30 $2.53B $2.57B 0.99
2017-06-30 $2.05B $2.51B 0.82
2017-03-31 $1.64B $2.43B 0.67
2016-12-31 $1.70B $2.61B 0.65
2016-09-30 $1.66B $2.67B 0.62
2016-06-30 $1.49B $2.63B 0.57
2016-03-31 $1.50B $2.63B 0.57
2015-12-31 $1.61B $2.57B 0.63
2015-09-30 $1.64B $2.52B 0.65
2015-06-30 $1.59B $2.54B 0.63
2015-03-31 $1.69B $2.48B 0.68
2014-12-31 $1.80B $2.66B 0.68
2014-09-30 $1.75B $2.71B 0.64
2014-06-30 $1.81B $2.76B 0.66
2014-03-31 $1.75B $2.73B 0.64
2013-12-31 $1.37B $2.72B 0.50
2013-09-30 $1.38B $2.68B 0.52
2013-06-30 $1.38B $2.60B 0.53
2013-03-31 $1.34B $2.69B 0.50
2012-12-31 $1.36B $2.72B 0.50
2012-09-30 $1.25B $2.71B 0.46
2012-06-30 $1.24B $2.64B 0.47
2012-03-31 $1.16B $2.64B 0.44
2011-12-31 $1.17B $2.56B 0.46
2011-09-30 $1.36B $2.59B 0.53
2011-06-30 $1.40B $2.59B 0.54
2011-03-31 $1.42B $2.54B 0.56
2010-12-31 $1.44B $2.48B 0.58
2010-09-30 $1.46B $2.43B 0.60
2010-06-30 $1.43B $2.34B 0.61
2010-03-31 $1.47B $2.31B 0.64
2009-12-31 $1.51B $2.29B 0.66
2009-09-30 $1.53B $2.23B 0.69
2009-06-30 $1.44B $1.54B 0.94
2009-03-31 $1.37B $1.46B 0.94
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.865B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00